Neoplasms of the bladder pose biologic and clinical challenges. Despite significant inroads into their origins and i mproved methods of diagnosis and treatment, they continue to exact a high toll in morbidity and mortality. The incidence of bladder epithelial tumors in the United States has been steadily increasing during the past years and is now more than 57,000 new cases annually.' Despite imp